v3.8.0.1

Commitments and Contingencies (Details Textual) - USD ($) |  |  | 3 Months Ended | 6 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Dec. 01, 2017 | Jul. 15, 2011 | Mar. 31, 2017 | Mar. 31, 2016 | Jun. 30, 2017 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Royalty Expense |  |  |  |  |  | $ 820,000 | $ 1,093,000 |
Accrued Liabilities, Current |  |  |  |  |  | 4,270,000 | 5,224,000 |
Accounts Payable, Current |  |  |  |  |  | 1,641,000 | 2,614,000 |
Business Combination, Contingent Consideration, Liability |  |  |  |  |  |  |  | $ 2,600,000
Revenues |  |  |  |  |  | 19,565,000 | 16,294,000 |
Installment Two [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Business Combination Agreed Contingent Consideration Payable Ratio In Excess Of Certain Revenue Targets |  |  | 3.5 |  |  |  |  |
Installment Two [Member] | Two Thousand Fifteen MIST Therapy [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Revenues |  |  | $ 10,200,000 |  |  |  |  |
Installment Two [Member] | Two Thousands Sixteen Mist Therapy [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Revenues |  |  | 10,500,000 |  |  |  |  |
Installment One [Member] | Two Thousand Fifteen MIST Therapy [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Revenues |  |  |  | $ 10,200,000 |  |  |  |
Installment One [Member] | Two Thousand Fourteen MIST Therapy [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Revenues |  |  |  | $ 8,700,000 |  |  |  |
AIQA Cedar Inc [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Accounts Payable, Current |  |  |  |  |  | 0 | 598,000 |
Alliqua Biomedical Subsidiary [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Contractual Obligation, Due in Next Twelve Months |  |  |  |  |  |  | 600,000 |
Royalty Expense |  |  |  |  |  | 1,900 |  |
Human Longevity, Inc [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Revenue Recognition, Milestone Method, Milestone Expenses |  |  |  |  |  |  | 1,000,000 |
Contingent Consideration [Member] | Installment Two [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Gross |  |  | $ 675,000 |  |  |  |  |
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares |  |  | 101,000 |  |  |  |  |
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned |  |  | $ 675,000 |  |  |  |  |
Contingent Consideration [Member] | Installment One [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Business Combination Agreed Contingent Consideration Payable Ratio In Excess Of Certain Revenue Targets |  |  |  | 3.5 |  |  |  |
Payments to Acquire Businesses, Gross |  |  |  | $ 2,600,000 |  |  |  |
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares |  |  |  | 98,600 |  |  |  |
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned |  |  |  | $ 2,600,000 |  |  |  |
Choice Therapeutics, Inc. [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares |  |  |  |  | 132,000 |  |  |
Business Combination, Contingent Consideration, Liability |  |  |  |  | $ 500,000 |  |  |
Cellularity Inc [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Royalty Expense |  |  |  |  |  | 818,000 | 493,000 |
Accrued Liabilities, Current |  |  |  |  |  | $ 227,000 | 197,000 |
Long-term Purchase Commitment, Amount | $ 842,000 |  |  |  |  |  |  |
Cellularity Inc [Member] | First Commercial Sale [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Contractual Obligation, Due in Next Twelve Months |  |  |  |  |  |  | 500,000 |
Cellularity Inc [Member] | Second Commercial Sale [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Contractual Obligation, Due in Next Twelve Months |  |  |  |  |  |  | $ 500,000 |
Noble Fiber Technologies License Agreement [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Royalty Fee Percentage |  | 9.75% |  |  |  |  |  |

X
- Definition The ratio of contingent consideration to be paid on certain revenue targets of products or services sold during the reporting period. + References No definition available. + Details
Name: | alqa_BusinessCombinationAgreedContingentConsiderationPayableRatioInExcessOfCertainRevenueTargets
Namespace Prefix: | alqa_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | alqa_CommitmentsAndContingenciesLineItems
Namespace Prefix: | alqa_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expenses related to milestone payments during the period. + References No definition available. + Details
Name: | alqa_RevenueRecognitionMilestoneMethodMilestoneExpenses
Namespace Prefix: | alqa_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition This element represent royalty payable equal to sale of licensed products. + References No definition available. + Details
Name: | alqa_RoyaltyFeePercentage
Namespace Prefix: | alqa_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_AccountsPayableCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_AccruedLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of contractual obligation due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_ContractualObligationDueInNextTwelveMonths
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The minimum amount the entity agreed to spend under the long-term purchase commitment. + References No definition available. + Details
Name: | us-gaap_LongTermPurchaseCommitmentAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=alqa_InstallmentTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=alqa_TwoThousandFifteenMistTherapyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=alqa_TwoThousandsSixteenMistTherapyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=alqa_InstallmentOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=alqa_TwoThousandFourteenMistTherapyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=alqa_AiqaCedarIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=alqa_AlliquaBiomedicalSubsidiaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=alqa_HumanLongevityIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=alqa_ContingentConsiderationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=alqa_ChoiceTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=alqa_CellularityIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=alqa_FirstCommercialSaleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=alqa_SecondCommercialSaleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=alqa_NobleFiberTechnologiesLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |